DB
TOVX icon

Danske Bank’s Theriva Biologics TOVX Stock Holding History

Danske Bank’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
1
– – ﹤0.01% 1219
2026
Q1 		$0 Hold
1
– – ﹤0.01% 1558
2025
Q4 		$0 Hold
1
– – ﹤0.01% 1632
2025
Q3 		$0 Hold
1
– – ﹤0.01% 1566
2025
Q2 		$0 Hold
1
– – ﹤0.01% 1587
2025
Q1 		$1 Hold
1
– – ﹤0.01% 1368
2024
Q4 		$2 Hold
1
– – ﹤0.01% 1385
2024
Q3 		$1 Buy
+1
New +$5 ﹤0.01% 1597

Other funds holding TOVX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return

Danske Bank's TOVX Position: Q2 2026 in Review

Danske Bank held its Theriva Biologics (TOVX) position steady in Q2 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

Danske Bank first reported a position in TOVX in Q3 2024 and has held it in 8 quarters since. The position peaked at $2 in Q4 2024. 15 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • Danske Bank held 1 share of Theriva Biologics worth $0 as of Q2 2026.
  • Danske Bank left its Theriva Biologics share count unchanged in Q2 2026.
  • Theriva Biologics made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1219 holding.
  • Danske Bank first reported a position in Theriva Biologics in Q3 2024 and has held it in 8 quarters since.
  • Danske Bank's Theriva Biologics position peaked at $2 in Q4 2024.
  • 15 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.